Mikhail Blagosklonny: Difference between revisions
Content deleted Content added
Undid revision 811167632 by 63.139.102.133 (talk) removal of sourced content |
m This is an unacceptable and prima facia reckless addition to a BLP page - do not revert this without finding consensus on the BLP noticeboard - I will be removing beall from wiki and nominating his page for deletion |
||
| Line 24: | Line 24: | ||
== Editorial activities== |
== Editorial activities== |
||
Blagosklonny is [[editor-in-chief]] of [[Aging (journal)|''Aging'']],<ref>{{Cite web |url=http://www.impactaging.com/editors.html |work=Aging |title=Editorial Board |accessdate=2016-11-20}}</ref> [[Cell Cycle (journal)|''Cell Cycle'']],<ref>{{Cite web |url=http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kccy20 |work=Cell Cycle |title=Editorial Board |accessdate=2016-11-20 |publisher=[[Taylor & Francis]]}}</ref> and ''[[Oncotarget]]''.<ref>{{Cite web |url=http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=pages&op=view&path%5B%5D=board |work=Oncotarget |title=Editorial Board |accessdate=2016-11-20}}</ref> In addition, he is associate editor of ''[[Cancer Biology & Therapy]]''<ref>{{cite web |url=http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kcbt20 |work=Cancer Biology & Therapy |title=Editorial board |publisher=Taylor & Francis|accessdate=2016-11-20}}</ref> and a member of the [[editorial board]] of ''[[Cell Death & Differentiation]]''.<ref>{{cite web |url=http://www.nature.com/cdd/about.html |work=[[Cell Death & Differentiation]] |title=About the journal |accessdate=2016-11-20}}</ref> |
Blagosklonny is [[editor-in-chief]] of [[Aging (journal)|''Aging'']],<ref>{{Cite web |url=http://www.impactaging.com/editors.html |work=Aging |title=Editorial Board |accessdate=2016-11-20}}</ref> [[Cell Cycle (journal)|''Cell Cycle'']],<ref>{{Cite web |url=http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kccy20 |work=Cell Cycle |title=Editorial Board |accessdate=2016-11-20 |publisher=[[Taylor & Francis]]}}</ref> and ''[[Oncotarget]]''.<ref>{{Cite web |url=http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=pages&op=view&path%5B%5D=board |work=Oncotarget |title=Editorial Board |accessdate=2016-11-20}}</ref> In addition, he is associate editor of ''[[Cancer Biology & Therapy]]''<ref>{{cite web |url=http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kcbt20 |work=Cancer Biology & Therapy |title=Editorial board |publisher=Taylor & Francis|accessdate=2016-11-20}}</ref> and a member of the [[editorial board]] of ''[[Cell Death & Differentiation]]''.<ref>{{cite web |url=http://www.nature.com/cdd/about.html |work=[[Cell Death & Differentiation]] |title=About the journal |accessdate=2016-11-20}}</ref> |
||
The reviewing process employed by ''Oncotarget'' has been criticized by [[Jeffrey Beall]],<ref name=Beall>{{cite web|last1=Beall |first1=Jeffrey |authorlink1=Jeffrey Beall |title=Oncotarget's Peer Review is Highly Questionable |url=https://scholarlyoa.com/2016/04/19/oncotargets-peer-review-is-highly-questionable/ |website=Scholarly Open Access |publisher=WordPress.com |accessdate=2016-11-20 |date=19 April 2016 |deadurl=yes |archiveurl=https://web.archive.org/web/20160420235706/https://scholarlyoa.com/2016/04/19/oncotargets-peer-review-is-highly-questionable/ |archivedate=20 April 2016 |df= }}</ref> who also included ''Oncotarget'' and ''Aging'' on his list of [[Predatory open access publishing|"potential, possible, or probable predatory scholarly open-access journals"]]<ref>{{cite web|last1=Beall |first1=Jeffrey |authorlink1=Jeffrey Beall |title=LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals |url=https://scholarlyoa.com/individual-journals/ |website=Scholarly Open Access |publisher=WordPress.com |accessdate=19 April 2016 |date=2016-11-20 |deadurl=yes |archiveurl=https://web.archive.org/web/20161202192038/https://scholarlyoa.com/individual-journals/ |archivedate=2 December 2016 |df= }}</ref> in July 2015.<ref name=Beall/> Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal impact factor.<ref>{{cite web|url=https://scholarlyoa.com/2016/12/06/mikhail-blagosklonnys-journal-aging-a-review/ |title=Mikhail Blagosklonny's Journal Aging: A Review |website=Scholarly Open Access |date=6 December 2016 |accessdate=17 January 2017 |archiveurl=https://web.archive.org/web/20161224004259/https://scholarlyoa.com/2016/12/06/mikhail-blagosklonnys-journal-aging-a-review/ |archivedate=24 December 2016 |deadurl=yes |df= }}</ref> |
|||
==Selected publications== |
==Selected publications== |
||
Revision as of 10:45, 20 November 2017
Mikhail Blagosklonny | |
|---|---|
| Alma mater | First Pavlov State Medical University of St. Peterburg |
| Scientific career | |
| Fields | Anti-aging medicine, oncology |
| Institutions | Roswell Park Cancer Institute |
Mikhail Blagosklonny is a scientist who studies cancer and aging. He was formerly a professor of oncology at the Roswell Park Cancer Institute in New York.[1]
Career
Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Peterburg.[1] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009 when he was appointed professor of oncology at Roswell Park Cancer Institute.[1]
Blogosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.[1]
Rapamycin and aging
Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[2] He is considered one of the most passionate advocates for rapamycin in longevity research.[3]
Editorial activities
Blagosklonny is editor-in-chief of Aging,[4] Cell Cycle,[5] and Oncotarget.[6] In addition, he is associate editor of Cancer Biology & Therapy[7] and a member of the editorial board of Cell Death & Differentiation.[8]
Selected publications
 | This section may contain unverified or indiscriminate information in embedded lists. (November 2016) |
Blagosklonny has published over 270 papers in peer-reviewed journals with over 25,000 citations, giving him an h-index of 83.[9]
- Blagosklonny, MV (Dec 2013). "TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists". Nature Cell Death & Disease. 4: e964. doi:10.1038/cddis.2013.506. PMC 3877573. PMID 24336084.
- Leontieva, OV; Demidenko, ZN; Blagosklonny, MV (Jun 2014). "Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program". PNAS. 111 (24): 8832–7. doi:10.1073/pnas.1405723111. PMC 4066505. PMID 24889617.
- Hypoxia, Blagosklonny MV. (Feb 2013). "MTOR and autophagy: converging on senescence or quiescence". Autophagy. 9 (2): 260–2. doi:10.4161/auto.22783. PMC 3552896. PMID 23192222.
- Leontieva, OV; Natarajan, V; Demidenko, ZN; Burdelya, LG; Gudkov, AV; Blagosklonny, MV (Aug 2012). "Hypoxia suppresses conversion from proliferative arrest to cellular senescence". PNAS. 109 (33): 13314–8. doi:10.1073/pnas.1205690109. PMC 3421205. PMID 22847439.
- Leontieva, OV; Demidenko, ZN; Gudkov, AV; Blagosklonny, MV (2011). "Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin". PLoS One. 6 (10): e26126. doi:10.1371/journal.pone.0026126. PMC 3191182. PMID 22022534.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - Demidenko, ZN; Fojo, T; Blagosklonny, MV (Apr 2005). "Complementation of two mutant p53: implications for loss of heterozygosity in cancer". FEBS Letters. 579 (10): 2231–5. doi:10.1016/j.febslet.2005.03.012. PMID 15811347.
- Blagosklonny, MV (2003). "Matching targets for selective cancer therapy". Drug Discov. Today. 8: 1104–7. doi:10.1016/s1359-6446(03)02806-x. PMID 14678733.
- Giannakakou, P; Nakano, M; Nicolaou, KC; O'Brate, A; Yu, J; Blagosklonny, MV; Greber, UF; Fojo, T (August 2002). "Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics". PNAS. 99: 10855–60. doi:10.1073/pnas.132275599. PMC 125062. PMID 12145320.
- Blagosklonny, MV (2002). "Oncogenic resistance to growth-limiting conditions". Nature Reviews Cancer. 2: 221–5. doi:10.1038/nrc743. PMID 11990858.
- Blagosklonny, MV (Apr 2002). "STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'". Nature Leukemia. 16 (4): 570–2. doi:10.1038/sj.leu.2402409. PMID 11960334.
- Blagosklonny, MV (Apr 2002). "Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs". Nature Leukemia. 16 (4): 455–62. doi:10.1038/sj.leu.2402415. PMID 11960322.
- Blagosklonny, MV. Pardee AB. (Mar 2002). "Conceptual biology: unearthing the gems". Nature. 416 (6879): 373. doi:10.1038/416373a. PMID 11919607.
- Blagosklonny, MV; Fojo, T; Bhalla, KN; Kim, JS; Trepel, JB; Figg, WD; Rivera, Y; Neckers, LM (2001). "The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy". Leukemia. 15: 1537–43. doi:10.1038/sj.leu.2402257. PMID 11587211.
- Blagosklonny, MV (2001). "Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells". Leukemia. 15: 936–41. doi:10.1038/sj.leu.2402127. PMID 11417480.
- Blagosklonny, MV (2001). "Unwinding the loop of Bcl-2 phosphorylation". Leukemia. 15: 869–74. doi:10.1038/sj.leu.2402134. PMID 11417471.
References
- ^ a b c d Roswell Park Cancer Center Mikhail Blagosklonny profile Page accessed November 30, 2016
- ^ "A New Path to Longevity". Scientific American. 306: 32–39. 2011. doi:10.1038/scientificamerican0112-32. Retrieved 2016-11-20.
- ^ "Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015". Retrieved November 20, 2016.
- ^ "Editorial Board". Aging. Retrieved 2016-11-20.
- ^ "Editorial Board". Cell Cycle. Taylor & Francis. Retrieved 2016-11-20.
- ^ "Editorial Board". Oncotarget. Retrieved 2016-11-20.
- ^ "Editorial board". Cancer Biology & Therapy. Taylor & Francis. Retrieved 2016-11-20.
- ^ "About the journal". Cell Death & Differentiation. Retrieved 2016-11-20.
- ^ "Mikhail Blagosklonny". Google Scholar. Google. Retrieved 2016-11-20.